Phase 3 N=969 Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
COVID-19
Primary: Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 — 5.0; 5.0 Days — p=0.880
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=758 Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Dry Eye Disease (DED)
Primary: Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) — 123; 121; 70 Participants
Phase 3 N=101 Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Long Term Follow up Dry Eye Disease
Primary: Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations — 0; 0; 0; 0 Participants
Phase 3 N=666 Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Leukemia, Myeloid, Acute
Primary: Objective Response (OR) — 38; 123 Participants — p=0.0024
Phase 3 N=366 Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 120; 131; 47 Participants
Phase 3 N=944 Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
Rhinosinusitis
Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set — -4.8213; -4.7394; -4.7758; -5.0180 Score on a scale
Phase 3 N=312 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Diffuse Large B-cell Lymphoma · de Novo DLBCL · DLBCL Transformed From Indolent Lymphoma
Primary: Progression Free Survival (PFS) — 7.3; 6.3 Months
Phase 3 N=340 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Breast Neoplasms
Primary: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date — 21.5; 13.9 Months — p=0.0012
Phase 3 N=827 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Endometrial Neoplasms
Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch…
Phase 3 N=648 A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: American College of Rheumatology(ACR)20 Response Rate at Week 24. — 268; 268 Participants
Phase 3 N=62 A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4 — 8.00; 8.16; 6.55; 7.07 scores on a scale
Phase 3 N=504 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…
Phase 3 N=298 Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in Hamilton Depression Scale (17 Items) (HAMD-17) Total Score — -9.0; -8.1 score on a scale — p=0.2956
Phase 3 N=130 Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Hyperphagia Behavior — -3.439; -5.372; -2.237 score on a scale — p=0.3493
Phase 3 N=140 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
Infraorbital Hollowing
Primary: Percentage of Participants With at Least a 1-point Improvement Change From Baseline on the Allergan Infraorbital Hollows Scale (AIHS) Based on Evaluating Investigator's…